Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma
Xiangke Xin, Xiaojian Zhu, Yang Yang, Na Wang, Jue Wang, Jinhuan Xu, Jia Wei, Liang Huang, Miao Zheng, Yi Xiao, Chunrui Li, Yang Cao, Fankai Meng, Lijun Jiang, Yicheng Zhang
Topics & Concepts
Chimeric antigen receptorRefractory (planetary science)LymphomaMedicineAntigenCancer researchSalvage therapyOncologyImmunologyInternal medicineT cellChemotherapyBiologyImmune systemAstrobiologyCAR-T cell therapy researchLymphoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers